Racura Oncology Ltd · ASX:RAC
Racura Oncology — Race Oncology — Shareholder Meeting (November 2025)
23 slides from Racura Oncology's shareholder meeting presentation, Nov 24, 2025
Slide 1: Race Oncology 2025 Chair's Address and AGM Presentation
ASX Announcement Race Oncology 2025 Chair’s Address and AGM Presentation 24 November 2025 – Race Oncology Limited (“Race”) is pleased to attach a copy of the Chair’s address and Annual General Meeting (AGM) presentation to shareholders. Dr Pete Smith, Executive Chair will provide the Chair’s address
Slide 2: Chair's Address – Race Oncology 2025 AGM
Chair’s Address – Race Oncology 2025 AGM 24 November 2025 Chair’s Address – Race Oncology 2025 AGM It has been a defining year for Race Oncology - one marked by disciplined execution, scientific insights, and a strengthening of our clinical and leadership foundations. The central highlight has been
Slide 3: Chair's Address (continued)
Importantly, our work in cardioprotection and anticancer activity with doxorubicin continues unchanged and remains a core priority. Together, these programs position RC220 as a versatile, high-value asset across solid tumours, orphan oncology indications, and large global markets. Importantly the G4
Slide 4: At the Heart of Cancer Care – CEO Address
N o v e m b e r 2 0 2 5 AT THE HEART OF CANCER CARE Dr Daniel Tillett – CEO & MD 2025 CEO AGM Presentation 0 ASX: RAC | RACE ONCOLOGY LIMITED | ABN 61 149 318 749 1
Slide 5: Continued evolution of Race Oncology
Continued evolution of Race Oncology A T T H E H E A R T Summary of recent positive events and evolved strategy of the company O F C A N C E R 1970s – 1990s 2020 – 2024 2025 Building on our history and progress C A R E Development by Phase 2 AML Filed Composition Current: Phase 1a/b cardioprotection
Slide 6: RC220 clinical pipeline
RC220 clinical pipeline A T T H E H E A R T Total Addressable Indication Phase 1 Phase 2 Phase 3 Comment Patients1 O F C A N C E R 40% response rate in 2 AML (RAC-030) Phase 2 trials3 US/EU: 50,000 C A R E Acute Myeloid Leukaemia2 Phase 3 Bisantrene approved in France for AML in 1988 Harness-1 (RAC-
Slide 7: Treatments where MYC dysregulation is associated with resistance
Treatments where MYC dysregulation is A T associated with resistance1 T H E H E A R T Target Indications Key drugs – Brand (generic), marketer, 2024 sales1 O F C A N C E R • Imbruvica® (ibrutinib), Janssen/Abbvie, US$6.35bn Bruton’s Tyrosine Kinase B-cell malignancies (leukemias and • Calquence® (ac
Slide 8: Tyrosine kinase inhibitor (TKI) market
Tyrosine kinase inhibitor (TKI) market1 A T TKIs are the backbone of modern, targeted cancer therapy T H E H E A R T O F C A N C E R C A R E 1. Source: Global Tyrosine Kinase Inhibitors Market By Type (June 2024) - https://marketresearch.biz/report/tyrosine-kinase-inhibitors-market/ 5
Slide 9: Clinical Trials
A T T H E H E A R T O F C A N C E R C A R E Clinical Trials EGFRm NSCLC, AML & CPACS 66
Slide 10: EGFR-mutated non-small cell lung cancer
EGFR-mutated non-small cell lung cancer A T T H E There is a large existing market for TKIs targeting the epidermal growth factor receptor (EGFR) H E A R T Target: Major Players – 3rd Generation TKIs Market dynamics O F Epidermal 2024 C A N C E R Growth Factor Receptor Brand Generic Manufacturer sal
Slide 11: HARNESS-1. HAlt Resistance in NSCLC with EGFR Sensitising mutationS
HARNESS-1. HAlt Resistance in NSCLC with A T EGFR Sensitising mutationS T H E H E A R T Addressing an urgent unmet need for patients who progress on third generation TKIs O F C A N C E R A Race Oncology sponsored Phase 1a/b trial of RC220 + osimertinib in EGFRm NSCLC patients who are tumour positive
Slide 12: HARNESS-1. Phase 1a/b Trial Overview
HARNESS-1. Phase 1a/b Trial Overview A T T H E Proof of concept trial demonstrating that RC220 can delay resistance to TKIs H E A R T O F ctDNA Screen EGFRm NSCLC patients on osimertinib (Osi) maintenance for tumour presence by C A N C E R Screening ctDNA (~100 patients) C A R E Phase 1a – dose esca
Slide 13: HARNESS-1 Trial Checklist
HARNESS-1 Trial Checklist A T T H E Requirement Feature of EGFRm NSCLC Check H E A R T Large existing market >US$10 billion p.a. for EGFRm TKIs O F Supportive preclinical & G4 binding targets more than three of the known EGFRm TKI C A N C E R clinical data resistance pathways C A R E High clinical n
Slide 14: AML Phase 3 Trial (RAC-030) ≥2nd Line
AML Phase 3 Trial (RAC-030) A T A rapid & affordable path to FDA-approval in the original indication of bisantrene T H E H E A R T Part A – RC110/RC220 Bridging & Project Optimus Part B – Dose Expansion O F C A N C E R RC110 DL 1 (250mg/m2 x 4d; n = 8) RC220 Optimum C A R E Dose3 (n = 97) RC220 DL 1
Slide 15: RC220 Phase 1 cardioprotection + anticancer synergy trial – CPACS-1 (RAC-010)
RC220 Phase 1 cardioprotection + anticancer A T synergy trial – CPACS-1 (RAC-010) T H E H E A R T Demonstrate RC220’s ability to protect the heart and increased anti-cancer efficacy O F C A N C E R Part 1: Advanced solid tumour patients how have the Part 2: Anthracycline naïve solid tumour patients
Slide 16: Intellectual Property
1313 A T T H E H E A R T O F C A N C E R C A R E Intellectual Property
Slide 17: Robust IP - Recent patent filings
Robust IP - Recent patent filings A T T H E Foundation for 20 years of the strongest composition of matter IP protection H E A R T • Race has discovered that bisantrene can exist in three forms that change when exposed O F to light – the (E,E), (E,Z) and (Z,Z) isoforms C A N C E R • Photoisomerisati
Slide 18: Milestones & Highlights
Milestones & Highlights 15
Slide 19: Future drivers of shareholder value
Future drivers of shareholder value1 A T Significant news flow and clinical data from three open-label trials in 2026 & 2027 T H E H E A R T 2026 2027 O F C A N C E R • Filing of US IND for Phase 3 AML (RAC-030) trial • First patient treated in Phase 1B CPACS (RAC-010) trial • Update on progress of
Slide 20: Key highlights of Race Oncology
Key highlights of Race Oncology A T T H E H E A R T 1 In Phase 3 with a derisked & clinically proven anticancer drug O F C A N C E R 2 Solving real & significant health problems – permanent damage caused by chemotherapy C A R E & TKI resistance 3 Targeting major existing markets as a companion to an
Slide 21: Final takeaway
Final takeaway A T T H E 1. There has been no change to the 2021 clinical programs H E A R T …but some highly valuable additions. CPACS and AML remain clear priorities for us O F C A N C E R 2. The timeline to a commercial outcome has not increased C A R E Update has significantly DECREASED the time
Slide 22: Questions
A T T H E H E A R T O F C A N C E R C A R E Questions Race Oncology A T T H E H E A R T O F C A N C E R C A R E 19
Slide 23: Contact
A T T H E H E A R T O F C A N C E R C A R E Contact DANIEL TILLETT CEO JANE LOWE Investor & Media Relations +61 2 8051 3043 +61 411 117 774 daniel.tillett@raceoncology.com jane.lowe@irdepartment.com.au www.raceoncology.com Authorised for release by the Board